Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Redescription of the genus Koumansetta (Teleostei: Gobiidae), with description of a new species from the Red Sea.

KovaČiĆ M, Bogorodsky SV, Mal AO, Alpermann TJ.

Zootaxa. 2018 Aug 15;4459(3):453-481. doi: 10.11646/zootaxa.4459.3.3.

PMID:
30314120
2.

Growth and bioactive secondary metabolites of arctic Protoceratium reticulatum (Dinophyceae).

Sala-Pérez M, Alpermann TJ, Krock B, Tillmann U.

Harmful Algae. 2016 May;55:85-96. doi: 10.1016/j.hal.2016.02.004. Epub 2016 Mar 2.

PMID:
28073550
3.

Bioactive compounds of marine dinoflagellate isolates from western Greenland and their phylogenetic association within the genus Alexandrium.

Tillmann U, Krock B, Alpermann TJ, Cembella A.

Harmful Algae. 2016 Jan;51:67-80. doi: 10.1016/j.hal.2015.11.004. Epub 2015 Dec 8.

PMID:
28003062
4.

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.

Chien W, Sun QY, Ding LW, Mayakonda A, Takao S, Liu L, Lim SL, Tan KT, Garg M, De Sousa Maria Varela A, Xiao J, Jacob N, Behrens K, Stocking C, Lill M, Madan V, Hattori N, Gery S, Ogawa S, Wakita S, Ikezoe T, Shih LY, Alpermann T, Haferlach T, Yang H, Koeffler HP.

Leukemia. 2017 Mar;31(3):762-766. doi: 10.1038/leu.2016.343. Epub 2016 Nov 24. No abstract available.

PMID:
27881871
5.

Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations.

Jeromin S, Haferlach C, Dicker F, Alpermann T, Haferlach T, Kern W.

Leukemia. 2016 Nov;30(11):2251-2253. doi: 10.1038/leu.2016.189. Epub 2016 Jul 14. No abstract available.

PMID:
27411488
6.

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP.

Leukemia. 2016 Dec;30(12):2430. doi: 10.1038/leu.2016.237. Epub 2016 Oct 7. No abstract available.

PMID:
27713533
7.

Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia.

Weber S, Haferlach T, Alpermann T, Perglerová K, Schnittger S, Haferlach C, Kern W.

Br J Haematol. 2016 Dec;175(5):904-916. doi: 10.1111/bjh.14343. Epub 2016 Sep 23.

PMID:
27662611
8.

Redescription of Cheilinus quinquecinctus Rüppell, 1835 (Pisces: Perciformes, Labridae), a valid endemic Red Sea wrasse.

Bogorodsky SV, Alpermann TJ, Mal AO.

Zootaxa. 2016 Aug 31;4158(4):451-72. doi: 10.11646/zootaxa.4158.4.1.

PMID:
27615897
9.

Maculabatis ambigua sp. nov., a new whipray (Myliobatiformes: Dasyatidae) from the Western Indian Ocean.

Last PR, Bogorodsky SV, Alpermann TJ.

Zootaxa. 2016 Aug 18;4154(1):66-78. doi: 10.11646/zootaxa.4154.1.4.

PMID:
27615825
10.

Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.

Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerová K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C.

Cancer. 2016 Dec 15;122(24):3821-3830. doi: 10.1002/cncr.30220. Epub 2016 Aug 16.

11.

Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).

Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, Garg M, Lim SL, Madan V, Hattori N, Nagata Y, Miyano S, Yeoh AE, Hou HA, Jiang YY, Takao S, Liu LZ, Tan SZ, Lill M, Hayashi M, Kinoshita A, Kantarjian HM, Kornblau SM, Ogawa S, Haferlach T, Yang H, Koeffler HP.

Leukemia. 2017 Jan;31(1):1-10. doi: 10.1038/leu.2016.160. Epub 2016 Jun 8.

12.

The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia.

Haferlach T, Stengel A, Eckstein S, Perglerová K, Alpermann T, Kern W, Haferlach C, Meggendorfer M.

Leukemia. 2016 Oct;30(10):2109-2112. doi: 10.1038/leu.2016.150. Epub 2016 May 23. No abstract available.

13.

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP.

Leukemia. 2016 Aug;30(8):1672-81. doi: 10.1038/leu.2016.69. Epub 2016 Apr 11. Erratum in: Leukemia. 2016 Dec;30(12 ):2430.

14.

BCOR regulates myeloid cell proliferation and differentiation.

Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP.

Leukemia. 2016 May;30(5):1155-65. doi: 10.1038/leu.2016.2. Epub 2016 Feb 5.

15.

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia.

Weber S, Haferlach C, Jeromin S, Nadarajah N, Dicker F, Noël L, Zenger M, Alpermann T, Kern W, Haferlach T, Schnittger S.

Genes Chromosomes Cancer. 2016 Feb;55(2):148-57. doi: 10.1002/gcc.22321. Epub 2015 Nov 6.

PMID:
26542308
16.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, Haferlach T.

Haematologica. 2016 Feb;101(2):e55-8. doi: 10.3324/haematol.2015.133819. Epub 2015 Oct 15. No abstract available.

17.

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.

Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP.

Blood. 2015 Nov 26;126(22):2491-501. doi: 10.1182/blood-2015-05-646240. Epub 2015 Oct 5.

18.

Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.

Fasan A, Haferlach C, Eder C, Alpermann T, Quante A, Peters A, Kern W, Haferlach T, Schnittger S.

Ann Hematol. 2015 Dec;94(12):1991-2001. doi: 10.1007/s00277-015-2488-7. Epub 2015 Sep 9.

PMID:
26351014
19.

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Meggendorfer M, de Albuquerque A, Nadarajah N, Alpermann T, Kern W, Steuer K, Perglerová K, Haferlach C, Schnittger S, Haferlach T.

Haematologica. 2015 Dec;100(12):e487-90. doi: 10.3324/haematol.2015.127985. Epub 2015 Aug 20. No abstract available.

20.

BRCC3 mutations in myeloid neoplasms.

Huang D, Nagata Y, Grossmann V, Radivoyevitch T, Okuno Y, Nagae G, Hosono N, Schnittger S, Sanada M, Przychodzen B, Kon A, Polprasert C, Shen W, Clemente MJ, Phillips JG, Alpermann T, Yoshida K, Nadarajah N, Sekeres MA, Oakley K, Nguyen N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Miyano S, Haferlach C, Kern W, Haferlach T, Du Y, Ogawa S, Makishima H.

Haematologica. 2015 Aug;100(8):1051-7. doi: 10.3324/haematol.2014.111989. Epub 2015 May 22.

21.

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.

Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, Hirsh C, Viny AD, Hosano N, Bleeker FE, Meggendorfer M, Alpermann T, Shiraishi Y, Chiba K, Tanaka H, van Noorden CJ, Radivoyevitch T, Carraway HE, Makishima H, Miyano S, Sekeres MA, Ogawa S, Haferlach T, Maciejewski JP.

Leukemia. 2015 Nov;29(11):2134-42. doi: 10.1038/leu.2015.91. Epub 2015 Apr 3.

22.

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

Alpermann T, Haferlach C, Eder C, Nadarajah N, Meggendorfer M, Kern W, Haferlach T, Schnittger S.

Leuk Res. 2015 Mar;39(3):265-72. doi: 10.1016/j.leukres.2014.11.026. Epub 2014 Dec 16.

PMID:
25592059
23.

Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.

Kern W, Bacher U, Haferlach C, Alpermann T, Schnittger S, Haferlach T.

Cytometry B Clin Cytom. 2015 May-Jun;88(3):154-64. doi: 10.1002/cyto.b.21224. Epub 2015 Mar 24.

24.

Rebuttal to Koeda et al. (2014) on the Red Sea fishes of the perciform genus Pempheris.

Randall JE, Victor BC, Alpermann TJ, Bogorodsky SV, Mal AO, Satapoomin U, Bineesh KK.

Zootaxa. 2014 Nov 25;3887(3):377-92. doi: 10.11646/zootaxa.3887.3.5.

PMID:
25543938
25.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S.

Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. No abstract available.

26.

Intraspecific facilitation by allelochemical mediated grazing protection within a toxigenic dinoflagellate population.

John U, Tillmann U, Hülskötter J, Alpermann TJ, Wohlrab S, Van de Waal DB.

Proc Biol Sci. 2015 Jan 7;282(1798):20141268. doi: 10.1098/rspb.2014.1268.

27.

Survey of demersal fishes from southern Saudi Arabia, with five new records for the Red Sea.

Bogorodsky SV, Alpermann TJ, Mal AO, Gabr MH.

Zootaxa. 2014 Aug 18;3852(4):401-37. doi: 10.11646/zootaxa.3852.4.1.

PMID:
25284408
28.

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, Schnittger S.

Haematologica. 2014 Dec;99(12):e244-6. doi: 10.3324/haematol.2014.113159. Epub 2014 Sep 19. No abstract available.

29.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2015 Mar;29(3):660-7. doi: 10.1038/leu.2014.243. Epub 2014 Aug 11.

PMID:
25110071
30.

Quantification of rare NPM1 mutation subtypes by digital PCR.

Bacher U, Dicker F, Haferlach C, Alpermann T, Rose D, Kern W, Haferlach T, Schnittger S.

Br J Haematol. 2014 Dec;167(5):710-4. doi: 10.1111/bjh.13038. Epub 2014 Jul 18. No abstract available.

PMID:
25039748
31.

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene.

Ommen HB, Hokland P, Haferlach T, Abildgaard L, Alpermann T, Haferlach C, Kern W, Schnittger S.

Br J Haematol. 2014 Jun;165(5):618-28. doi: 10.1111/bjh.12792. Epub 2014 Feb 24.

PMID:
24611505
32.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.

Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S.

Blood Cancer J. 2014 Jan 10;4:e173. doi: 10.1038/bcj.2013.71.

33.

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2014 Jul;28(7):1449-58. doi: 10.1038/leu.2014.4. Epub 2014 Jan 9.

PMID:
24402164
34.

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.

Bacher U, Haferlach T, Schnittger S, Zenger M, Meggendorfer M, Jeromin S, Roller A, Grossmann V, Krauth MT, Alpermann T, Kern W, Haferlach C.

Br J Haematol. 2014 Mar;164(6):822-33. doi: 10.1111/bjh.12710. Epub 2013 Dec 26.

PMID:
24372512
35.

Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization.

Kern W, Bacher U, Schnittger S, Dicker F, Alpermann T, Haferlach T, Haferlach C.

Br J Haematol. 2014 Feb;164(4):565-9. doi: 10.1111/bjh.12652. Epub 2013 Nov 14.

PMID:
24236747
36.

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S.

Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.

37.

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A, Haferlach T, Kern W, Schnittger S.

Leukemia. 2014 Jan;28(1):108-17. doi: 10.1038/leu.2013.263. Epub 2013 Sep 12.

PMID:
24113472
38.

Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma.

Bacher U, Kern W, Haferlach C, Alpermann T, Haferlach T, Schnittger S.

Exp Hematol. 2013 Dec;41(12):1028-37. doi: 10.1016/j.exphem.2013.09.004. Epub 2013 Sep 20.

PMID:
24060591
39.

The role of different genetic subtypes of CEBPA mutated AML.

Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S.

Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23.

PMID:
24056881
40.

[FeFe]-hydrogenase models assembled into vesicular structures.

Menzel K, Apfel UP, Wolter N, Rüger R, Alpermann T, Steiniger F, Gabel D, Förster S, Weigand W, Fahr A.

J Liposome Res. 2014 Mar;24(1):59-68. doi: 10.3109/08982104.2013.833225. Epub 2013 Sep 5.

PMID:
24006843
41.

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, Roller A, Kern W, Haferlach C, Schnittger S, Haferlach T.

Leukemia. 2014 Jan;28(1):129-37. doi: 10.1038/leu.2013.239. Epub 2013 Aug 20.

PMID:
23958918
42.

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.

Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, Ishikawa S, Sato-Otsubo A, Nagae G, Nishimoto A, Haferlach C, Nowak D, Sato Y, Alpermann T, Nagasaki M, Shimamura T, Tanaka H, Chiba K, Yamamoto R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Nakamaki T, Ishiyama K, Nolte F, Hofmann WK, Miyawaki S, Chiba S, Mori H, Nakauchi H, Koeffler HP, Aburatani H, Haferlach T, Shirahige K, Miyano S, Ogawa S.

Nat Genet. 2013 Oct;45(10):1232-7. doi: 10.1038/ng.2731. Epub 2013 Aug 18.

PMID:
23955599
43.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

44.

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.

Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S.

Leukemia. 2013 Sep;27(9):1852-60. doi: 10.1038/leu.2013.133. Epub 2013 Apr 30.

PMID:
23628959
45.

Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.

Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S; MPN and MPNr-EuroNet (COST Action BM0902).

Leukemia. 2013 Sep;27(9):1826-31. doi: 10.1038/leu.2013.120. Epub 2013 Apr 18.

PMID:
23594705
46.

Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.

Fasan A, Alpermann T, Haferlach C, Grossmann V, Roller A, Kohlmann A, Eder C, Kern W, Haferlach T, Schnittger S.

PLoS One. 2013;8(2):e54365. doi: 10.1371/journal.pone.0054365. Epub 2013 Feb 1.

47.

Patterns of post-glacial genetic differentiation in marginal populations of a marine microalga.

Tahvanainen P, Alpermann TJ, Figueroa RI, John U, Hakanen P, Nagai S, Blomster J, Kremp A.

PLoS One. 2012;7(12):e53602. doi: 10.1371/journal.pone.0053602. Epub 2012 Dec 31.

48.

Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.

Kern W, Bacher U, Schnittger S, Alpermann T, Haferlach C, Haferlach T.

Cytometry B Clin Cytom. 2013 May;84(3):194-7. doi: 10.1002/cyto.b.21068. Epub 2013 Jan 2.

49.

Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.

Alpermann T, Kern W, Schnittger S, Schmid C, Kreuzer KA, Serve H, Pielken HJ, Schmitz N, Wendtner CM, Haferlach C, Haferlach T.

Leuk Res. 2013 Feb;37(2):197-200. doi: 10.1016/j.leukres.2012.11.008. Epub 2012 Dec 10.

PMID:
23237559
50.

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann HE, Kreuzer KA, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2013 Jan;27(1):82-91. doi: 10.1038/leu.2012.262. Epub 2012 Sep 11.

PMID:
23018865

Supplemental Content

Loading ...
Support Center